Genmab announces data on all evaluable patients in HuMax-CD20 NHL Phase I/II study
Responders include one additional patient compared to the data previously reported in June. The new responding patient had previously responded to rituximab. This increases the objective response rate in patients who previously responded to rituximab treatment to 64% (9 of 14 patients), including 3 CR, 1 CRu and 5 PR.
The median duration of response and median time to disease progression in responding patients have not yet been reached after 12 months of follow up. Of the 16 patients who responded to treatment, 12 have not progressed at the end of the follow up period.
HuMax-CD20 was well tolerated by the patients in the study. No dose limiting toxicities were reported and the maximum tolerated dose was not reached.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.